An interventional study of Supporting Patients by Family Education in Psychotic Illness Group in Psychotic Disorders, Family Members and Anosognosia, sponsored by University of Alberta. Recruiting at 4 sites in Canada. Open to participants aged 17 Years to 27 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University of Alberta · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 148 studies in Psychotic Disorders with a site in Canada — 32 open to participants now, 41 under way, 2 of them phase 3. Psychotic Disorders · Canada.
Among the 148 studies in Psychotic Disorders with a site in Canada, this one is the 28th largest by planned enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2022, is one of 86 with no phase, reaches primary completion later than 36 of the 40 other live ones, and was the 115th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →32 of the 148 studies in Psychotic Disorders with a site in Canada are open now. Recruiting first, the newest first:
Douglas Mental Health University Institute · Sites in Canada
Ages 18–34
McMaster University · Sites in Canada
Ages 18–35
University of Toronto · Sites in Canada
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 16–30
Bristol-Myers Squibb · Sites in Canada, United States, Australia and 2 more countries
Ages 55–90
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 17 Years to 27 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 10 · Phase 4 10
First in 1999; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 113 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 58 across the 117 interventional studies, 109 across the 30 observational. Of the 88 that completed or were terminated, 14 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 148 have an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
University of Alberta has 1 study filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
11 of the studies in Psychotic Disorders with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04338152University of California, Los AngelesFamily-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial | 2026-12-30 |
| NCT05704582Ciusss de L'Est de l'Île de MontréalRCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders | 2027-01 |
| NCT05731414University of TorontoOutcomes From Remediation and Behavioural Intervention Techniques | 2027-01-31 |
| NCT04033679Centre for Addiction and Mental HealthThe Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia | 2027-03 |
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 148 studies in Psychotic Disorders with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: A lack of education, resources, and support for family carers of young adults with psychotic illnesses leaves them ill-equipped to support their loved one. Although family support groups exist, few groups offer evidence-based, skills-focused, psychoeducation taught by certified professionals and provided on a public-health level. By equipping families with skills and knowledge, public healthcare harnesses a powerful ally to maintain community stabilization.
Aims: The primary study goal is to implement a psychoeducation intervention for family carers supporting young adults with psychosis to reduce family burden and foster community stabilization of service users.
Methods: A longitudinal pre-post design will be used to assess the long-term effectiveness of the psychoeducation intervention for family carers supporting a young adult with psychosis on service utilization and functional indexes. Nine expert-reviewed, and family peer-informed psychoeducation modules are administered in 2-hour sessions over 9 weeks to family carers.
Conclusion: Presenting the novel approach of an expert-reviewed, peer-informed psychoeducation intervention for family carers, with a focus on knowledge and skill development, the researchers contribute to literature and best practice in patient and family-centered care.
Background:
A lack of education, resources, and support for family carers of young adults with psychotic illnesses leaves them ill-equipped to support their loved one. Often family carers are excluded from the discharge planning process or are unaware of how to support of their loved one in community. Although best practice documents champion family involvement the implementation of these guidelines is challenge and families are often excluded from care.There is evidence of the disparity between best practice documents and true practice in the literature.
Family inclusion also addresses the impact of psychotic disease on the family's functioning and mental health. Psychotic illness (e.g., anosognosia, paranoia) can interfere with relational health and the natural maturation of family relationships over time. Families face extreme challenges when supporting a young adult with psychotic illness including social isolation, likely because their typical social supports are unable to relate to their situation, prompting them to seek support with those who share their situation (i.e., family support groups). Family carers, even in the face of these hardships, work with great tenacity toward improving service user stability in community.
There is a lack of high-quality effectiveness research showing longitudinal evidence for treatment effects on the carer and the young person in family psychoeducation groups. For example, one study provided a family intervention that was primarily knowledge- and support-based. These researchers used a pre-post design to assess the mental health knowledge, but did not assess long-term effectiveness of the group, overall family functioning, and functioning of the service user.
The intent for this longitudinal pre-post study is to evaluate the effect of skills-based educational programming for family carers supporting young adults admitted to or discharged from hospital with psychosis of any etiology on 6-month and 24-month service user readmission rates and service user/family functional indexes. The investigators hypothesize that system integration of a program which delivers early support for the family carers by way of an educational intervention beginning prior to or shortly after hospital discharge may reduce family burden as well as improve short- and long-term patient outcomes. To the investigators' knowledge, this study is the first to evaluate effectiveness of a family carer skills-based education intervention within a public healthcare system.
The investigators will use a longitudinal pretest-posttest design with a non-equivalent control group to evaluate the short- and long-term effectiveness of this family psychoeducation intervention. While a control group can be used for comparison of the service utilization data for young adults with psychosis using archival data from health records, gathering long-term control group data from families not participating in the trial is unethical in that denial of an intervention for up to two years is potentially harmful to both the families and the young adult they support. Likewise, control group data gathered directly from young adult service users presents the same ethical problem. Using archival health utilization data, however, allows us to exclude any service users' whose families have elected to access the psychoeducation program within the 2-year timeframe of the study. This allows us to find control data for health service utilization while not withholding the psychoeducation intervention from those who seek it. The investigators acknowledge that the control group is non-equivalent because families and service users who chose not to engage in the study may vary systematically from those who did.
Each measure will be taken pre-intervention (i.e., baseline), post-intervention, then again at 6- and 24-months post-intervention. A gift card incentive ($25.00 per data collection meeting) will be provided to family and young adult participants as a token of appreciation for their participation.
Service utilization data will be collected for 12-months pre-intervention to be compared to 12-months post-intervention and 12-24 months post-intervention.
Recruitment:
Study information will be disseminated by clinical teams and through community organizations, and family carers meeting eligibility criteria will self-identify for participation. Once recruited, and with family consent, young adult service users of participating family carers will be contacted for recruitment into the study.
Measures:
A variety of measures will be used to collect functional index data for the family members and the young adult service users. Health utilization data will be mined for 12-months pre-intervention, and up to 24-months post-intervention to assess long term service user outcomes. See Outcome Measures section for details.
Secondary Data Control Group:
While randomization into treatment and control groups was not feasible for this study, non-equivalent control group data can be mined from health records for young adults whose family did not participate in the study.
Intervention:
The educational modules are developed by experts in the areas of interest and are evidence based, family peer-informed and expert peer-reviewed. The curriculum consists of 9 modules delivered weekly over 9 weeks. Evidence-based content includes the Listen-Empathize-Agree-Partner (LEAP) communication Program, and Acceptance and Commitment Therapy. The family psychoeducation classes are to take place at a designated AHS location.
Limitations and Conclusion:
The described protocol is one of the first attempts in the literature to evaluate an evidence-based intervention for carers of young adults with psychotic illness. The current study builds on others by incorporating psychoeducational elements, modules specific to the LEAP approach, and modules specific to ACT. Furthermore, the design of the study intends to gather longitudinal 24-month post-intervention data from carers and service users, including health service utilization data.
Several limitations must be considered with regards to this protocol. First, using a pre-post design the investigators cannot draw causal conclusions regarding the effect of the intervention. To address this limitation the investigators will use secondary data from health records as a non-equivalent control group for health utilization data. A second limitation is that participants self-select for the study, and may differ systematically from those who choose not to participate. For example, the sample will likely be biased towards families who are already supportive and involved in their young adults' care. The sample of young adults participating will be additionally biased because those who are especially unwell may be unable to participate. By comparing the health utilization data of the participants to the nonequivalent control group in a longitudinal design the investigators will gain some evidence to rule out history effects. Even with these limitations, the described design builds on existing knowledge of effective family psychoeducation groups and their long term effects on young adults experiencing psychosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
These participants will receive the psychoeducation intervention and outcome measures will be taken from them and their young adult service user. The intervention includes psychoeducation on stages of a family's journey, the biopsychosocial basis of psychosis, and skills for coping (Acceptance and Commitment Therapy for Caregivers) and communicating (LEAP).
Behavioral: Supporting Patients by Family Education in Psychotic Illness Group
Psychoeducation for families supporting young adults with psychosis.
Family Burden Interview Schedule
assesses overall burden of the family related to supporting a loved one with addiction and mental health concerns, including the following domains: financial, routines and activities, leisure, relationships, physical health, mental health
Time frame: Baseline-Day 0 (Pre-intervention)
Family Burden Interview Schedule
assesses overall burden of the family related to supporting a loved one with addiction and mental health concerns, including the following domains: financial, routines and activities, leisure, relationships, physical health, mental health
Time frame: 9-Week Follow-Up (Post-Intervention)
Family Burden Interview Schedule
assesses overall burden of the family related to supporting a loved one with addiction and mental health concerns, including the following domains: financial, routines and activities, leisure, relationships, physical health, mental health
Time frame: 6-Month Follow-Up (Post-Intervention)
Family Burden Interview Schedule
assesses overall burden of the family related to supporting a loved one with addiction and mental health concerns, including the following domains: financial, routines and activities, leisure, relationships, physical health, mental health
Time frame: 24-Month Follow-Up (Post-Intervention)
Positive and Negative Symptom Schedule
assesses overall symptom severity of service users, including 7 positive symptoms (e.g., hallucinations, grandiosity, etc.), 7 negative symptoms (e.g., blunted affect, emotional withdrawal) and general symptoms (e.g., anxiety, lack of judgement/insight, poor impulse control)
Time frame: Baseline-Day 0 (Pre-intervention)
Positive and Negative Symptom Schedule
assesses overall symptom severity of service users, including 7 positive symptoms (e.g., hallucinations, grandiosity, etc.), 7 negative symptoms (e.g., blunted affect, emotional withdrawal) and general symptoms (e.g., anxiety, lack of judgement/insight, poor impulse control)
Time frame: 9-Week Follow-Up (Post-Intervention)
Positive and Negative Symptom Schedule
assesses overall symptom severity of service users, including 7 positive symptoms (e.g., hallucinations, grandiosity, etc.), 7 negative symptoms (e.g., blunted affect, emotional withdrawal) and general symptoms (e.g., anxiety, lack of judgement/insight, poor impulse control)
Time frame: 6-Month Follow-Up (Post-Intervention)
Positive and Negative Symptom Schedule
assesses overall symptom severity of service users, including 7 positive symptoms (e.g., hallucinations, grandiosity, etc.), 7 negative symptoms (e.g., blunted affect, emotional withdrawal) and general symptoms (e.g., anxiety, lack of judgement/insight, poor impulse control)
Time frame: 24-Month Follow-Up (Post-Intervention)
Manchester Short Assessment of Quality of Life
assessing service user quality of life on a scale of 1 (couldn't be worse) to 7 (couldn't be better) and "yes/no" for select items.
Time frame: Baseline-Day 0 (Pre-intervention)
Manchester Short Assessment of Quality of Life
assessing service user quality of life on a scale of 1 (couldn't be worse) to 7 (couldn't be better) and "yes/no" for select items.
Time frame: 9-Week Follow-Up (Post-Intervention)
Manchester Short Assessment of Quality of Life
assessing service user quality of life on a scale of 1 (couldn't be worse) to 7 (couldn't be better) and "yes/no" for select items.
Time frame: 6-Month Follow-Up (Post-Intervention)
Manchester Short Assessment of Quality of Life
assessing service user quality of life on a scale of 1 (couldn't be worse) to 7 (couldn't be better) and "yes/no" for select items.
Time frame: 24-Month Follow-Up (Post-Intervention)
Inpatient Readmission Rate
Readmission rate for mental health diagnosis within 30 days of an inpatient discharge
Time frame: 12-24 months post-intervention
Inpatient Readmission Rate
Readmission rate for mental health diagnosis within 30 days of an inpatient discharge
Time frame: 12-months pre-intervention
Inpatient Readmission Rate
Readmission rate for mental health diagnosis within 30 days of an inpatient discharge
Time frame: 12-months post-intervention
Inpatient Admission Frequency
Frequency of hospital admissions for mental health diagnosis
Time frame: 12-months pre-intervention
Inpatient Admission Frequency
Frequency of hospital admissions for mental health diagnosis
Time frame: 12-months post-intervention
Inpatient Admission Frequency
Frequency of hospital admissions for mental health diagnosis
Time frame: 12-24 months post-intervention
Emergency Department Visit Frequency
Frequency of emergency departments visits within 30 days of last emergency presentation
Time frame: 12-months pre-intervention
Emergency Department Visit Frequency
Frequency of emergency departments visits within 30 days of last emergency presentation
Time frame: 12-months post-intervention
Emergency Department Visit Frequency
Frequency of emergency departments visits within 30 days of last emergency presentation
Time frame: 12-24 months post-intervention
Community Appointment Frequency
Appointment frequency for community-based services
Time frame: 12-months pre-intervention
Community Appointment Frequency
Appointment frequency for community-based services
Time frame: 12-months post-intervention
Community Appointment Frequency
Appointment frequency for community-based services
Time frame: 12-24 months post-intervention
Crisis Service Frequency
Frequency of crisis calls and visits
Time frame: 12-months pre-intervention
Crisis Service Frequency
Frequency of crisis calls and visits
Time frame: 12-months post-intervention
Crisis Service Frequency
Frequency of crisis calls and visits
Time frame: 12-24 months post-intervention
Plan to share: Yes — All IPD datasets that will be collected and analyzed for this study will be available by request from the corresponding author. Given the small study population, narrow geographic region of recruitment, and Alberta Health Services\' data sharing policies, potentially identifying demographic data will not be available.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available to requesting individuals/organizations through the corresponding author for a timeframe appropriate to the requesting party\'s needs.
Access criteria: The purpose and timeframe of the requesting individuals/organizations dataset access will be reviewed on a case by case basis by the research team and is subject to approval by Alberta Health Services based on data sharing policies.
Started Sep 2022 (actual). Primary completion is estimated for Dec 2028, 75 months after the start.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 75 months is above that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Sep 2026 → Dec 2028 and completion Sep 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.